$ABBV with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NYSE:ABBV after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 66.67%.Longby EPSMomentum0
ABBVIE Any pull-back is a buy opportunity.AbbVie Inc. (ABBV) is having the strongest 1D candle since October 13 2022, hitting the 1D MA200 (orange trend-line) for the first time in almost three months. The long-term pattern is a Channel Down and this one is the bullish leg to a new Lower High. The 1D RSI has breached into overbought (70.00>) territory so any pull-back is a buy, even on the current levels. Our medium-term target is the 0.786 Fibonacci retracement level (158.50) similar to what happened on the December 09 2022 High. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇Longby TradingShot117
ABBV looks good for me to buy now As it shown on the chart NYSE:ABBV it is a good zone to open a new position because it is trading near by a daily support My Stop Loss 4 Hours close lower than the support zone 133$ What do you think about ABBV ? Longby MhAlbeloshiUpdated 1
ABBV - Possible supply zoneThis stock have a hard time. Fundamental headwinds set -20% on the chart. But now a consolidation seems to kick in. If you like this long term, this could be a decent entry. by DenAlmindeligeFar0
ABBV Breakout ImminentABBV looks poised to break out after finding Weekly/Monthly support. Targeting the 50 Moving Average on the Hourly Chart sitting at 140$ for a short term trade. Watching positive crossing of the CCI zero line for additional confirmation as it has been diverging for a while now. Longby Midgar-Updated 1
ABBV more probable to go down first before reaching ATHThis idea is based on Wyckoff's method for determining price objectives using the Point & Figure count of distribution ranges. We can a distribution ranges following schematic 2 for Wyckoff's distribution. If we take count the ranges separately, this yields a potential reversal zone between 118.50 and 94.50 dollar per share. Personally I am intend to buy if price reached 106.50 (mid point) All other information is on the chart. Good luck, NQDecipherShortby NQunlocked1
ABBV: Approaching toward support zone [127.9/129.3]ABBV stock's price is approaching toward a support zone between 127.9 and 129.3 where a possible rebound toward 158.6 is expected. Support zone= 127.9/129.3 Target=158.6Longby Quantific-Solutions1
$ABBV with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NYSE:ABBV after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 66.67%.Longby EPSMomentum1
How to Trade Three White SoldiersHow to trade three white soldiers patterns with entries and stop levels.Longby bullishbears1
ABBVBreaking down out of the triangle at the 1.618 extension. Needs a hard reversal around this level or else price probably makes its way back down to $120s.Shortby Essendy221
ABBV rejecting from cluster resistance 🥶we most likely dip to trend support/153 area or lower if we reject here.. longs could work over 168.50.. but i doubt that comes anytime soon.. boost and follow for more 💛Shortby Vibranium_CapitalUpdated 1111
ABBV Long setupLooking for an upswing soon, waiting on confirmation from my Algo to go cuz I don't know. KISS- Keep It Simple (Long) SupportLongby MegaTroy2
ABBV AbbVie Options Ahead of EarningsAnalyzing the options chain of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 175usd strike price Calls with an expiration date of 2024-1-19 for a premium of approximately $6.90. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. I am interested to hear your thoughts on this strategy. Longby TopgOptions5
ABBV at resistance of trend lineBased on weekly timeframe, ABBV at resistance of trend line.by Trader89101
$ABBV possible short this week, turning to a long on the bottomNYSE:ABBV looking like a nice potential short coming soon if we reject the top of this wedge. Possible rejection down to the previous resistance turned support flip. Next level of course is the bottom of the wedge. by linuxboytoo0
ABBV daily bullish hammer beginning of wave 3 wave 5 uptrendOrder BUY ABBV NYSE Stop 145.78 LMT 145.78 will be automatically canceled at 20230401 01:00:00 EST ABBV daily bullish hammer beginning of wave 3 wave 5 uptrend that was ABC correction.Longby MishaSuvorovUpdated 4
Monthly 3-2-2 reversal Target:200$ Hello dear Traders, Here is my idea for #ABBV Price closed above yellow line Target marked in the chart Invalidation level marked with red line IV30 % Rank: 2% Subdued Good luck! ❤️Please feel free to ask any question in comments. I will try to answer all! Thank you. Please, support my work with like, thank you!❤️Longby Diplo_Trades1
$ABBV with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $ABBV after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 63.64%.Longby EPSMomentum1
ABBV bear flag breakABBV has been in a down trend since the start of the year. With a break of the bear flag there is now only the long term trendline to save it.by rherricks1
ABBV Long-term buy confirmedAbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the most optimal buy signal an investor can have. As you see on this 1D chart, the stock had 4 Higher High touches during that period and the only time the price broke above the Channel Up was on February 16 2022 the break-out of which peaked on April 08 2022. With the help of the Fibonacci Channel levels we can see why the price stopped where it stopped. In fact we also see the important role of the median (Fib 0.5). Based on the above, we expect a new Higher high around the $180.00 price mark. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇Longby TradingShot1110
ABBV | Loading this Drug Company | LONGAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Longby DivergenceSeekerUpdated 224
Sell ABBVABBV had a double top on higher time frames, i'd be very cautious. The 2 big support areas i see are $134 and $99.Shortby MaustyUpdated 3